Atossa Therapeutics, Inc. (ATOS)
ATOS Stock Price Chart
Explore Atossa Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ATOS price movements and trends.
ATOS Company Profile
Discover essential business fundamentals and corporate details for Atossa Therapeutics, Inc. (ATOS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Nov 2012
Employees
16.00
CEO
Steven C. Quay
Description
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
ATOS Financial Timeline
Browse a chronological timeline of Atossa Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$1.04.
Earnings released on 8 May 2026
EPS came in at -$1.11 surpassing the estimated -$1.22 by +9.02%.
Earnings released on 25 Mar 2026
EPS came in at -$1.19 falling short of the estimated -$1.14 by -4.62%.
Stock split effective on 2 Feb 2026
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Nov 2025
EPS came in at -$1.05 matching the estimated -$1.05.
Earnings released on 12 Aug 2025
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%.
Earnings released on 13 May 2025
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 25 Mar 2025
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 12 Nov 2024
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 12 Aug 2024
EPS came in at -$0.05 matching the estimated -$0.05.
Earnings released on 13 May 2024
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%.
Earnings released on 1 Apr 2024
EPS came in at -$0.06 falling short of the estimated -$0.05 by -20.00%, while revenue for the quarter reached $18.00k .
Earnings released on 13 Nov 2023
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%.
Earnings released on 14 Aug 2023
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 15 May 2023
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 22 Mar 2023
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 7 Nov 2022
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 8 Aug 2022
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 9 May 2022
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%.
Earnings released on 28 Feb 2022
EPS came in at -$0.04 falling short of the estimated -$0.04 by -11.11%.
Earnings released on 15 Nov 2021
EPS came in at -$0.04 falling short of the estimated -$0.04 by -11.11%.
Earnings released on 13 Aug 2021
EPS came in at -$0.06 falling short of the estimated -$0.04 by -71.43%.
ATOS Stock Performance
Access detailed ATOS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
